Patent eligibility and biosecurity governance of CRISPR gene editing, synthetic cellular organisms, recombinant DNA, and genomic privacy.
Bio-jurisprudence balances the incentive to invent novel biological therapies with the prohibition against monopolizing natural phenomena. The landmark distinction established in AMP v. Myriad isolates unpatentable naturally occurring DNA sequences from patent-eligible synthetic cDNA and CRISPR engineering vectors. Biosecurity regulations now require gene synthesis vendors to algorithmically verify customer credentials and sequence hazards.
The global patent priority split evaluating whether transferring prokaryotic guide-RNA CRISPR systems into eukaryotic human cells was obvious under 35 U.S.C. § 103.
The definitive Supreme Court rule holding that naturally occurring DNA sequences (such as BRCA1/BRCA2) are unpatentable products of nature, whereas synthetic cDNA remains eligible.
Mandatory biosecurity protocols requiring commercial gene synthesis providers to verify customer identities and algorithmically screen orders for select toxin agents.
Federal biosecurity frameworks under Executive Order 14110 and HHS guidelines mandate commercial gene synthesis providers to verify customer identities and screen all orders against select pathogen databases.
